{"corpus_id":241185914,"paper_sha":"ff6768e25bde324a1df0f71a54de2afc537ca743","doi":"10.1016/j.eclinm.2022.101331","arxiv_id":null,"pmid":35360146,"pmcid":"8961170","mag_id":null,"dblp_id":null,"acl_id":null,"title":"Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis","year":2022,"publication_date":"2022-03-25","venue":"EClinicalMedicine","journal":{"name":"EClinicalMedicine","pages":null,"volume":"46"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","Review"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":32,"citation_count":56,"influential_citation_count":3,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"http://www.thelancet.com/article/S258953702200061X/pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/ff6768e25bde324a1df0f71a54de2afc537ca743","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Summary Background Influenza is one of the most common respiratory viral infections worldwide. Numerous vaccines are used to prevent influenza. Their selection should be informed by the best available evidence. We aimed to estimate the comparative efficacy and safety of seasonal influenza vaccines in children, adults and the elderly. Methods We conducted a systematic review and network meta-analysis (NMA). We searched the Cochrane Library Central Register of Controlled Trials, MEDLINE and EMBASE databases, and websites of regulatory agencies, through December 15th, 2020. We included placebo- or no vaccination-controlled, and head-to-head randomized clinical trials (RCTs). Pairs of reviewers independently screened the studies, abstracted the data, and appraised the risk of bias in accordance to the Cochrane Handbook for Systematic Reviews of Interventions. The primary outcome was laboratory-confirmed influenza. We also synthesized data for hospitalization, mortality, influenza-like illness (ILI), pneumonia or lower respiratory-tract disease, systemic and local adverse events (AEs). We estimated summary risk ratios (RR) using pairwise and NMA with random effects. This study is registered with PROSPERO, number CRD42018091895. Findings We identified 13,439 citations. A total of 231 RCTs were included after screening: 11 studies did not provide useful data for the analysis; 220 RCTs [100,677 children (< 18 years) and 329,127 adults (18–60 years) and elderly (≥ 61 years)] were included in the NMA. In adults and the elderly, all vaccines, except the trivalent inactivated intradermal vaccine (3-IIV ID), were more effective than placebo in reducing the risk of laboratory-confirmed influenza, with a RR between 0.33 (95% credible interval [CrI] 0.21–0.55) for trivalent inactivated high-dose (3-IIV HD) and 0.56 (95% CrI 0.41–0.74) for trivalent live-attenuated vaccine (3-LAIV). In adults and the elderly, compared with trivalent inactivated vaccine (3-IIV), no significant differences were found for any, except 3-LAIV, which was less efficacious [RR 1.41 (95% CrI 1.04–1.88)]. In children, compared with placebo, RR ranged between 0.13 (95% CrI 0.03–0.51) for trivalent inactivated vaccine adjuvanted with MF59/AS03 and 0.55 (95% CrI 0.36–0.83) for trivalent inactivated vaccine. Compared with 3-IIV, 3-LAIV and trivalent inactivated adjuvanted with MF59/AS03 were more efficacious [RR 0.52 (95% CrI 0.32–0.82) and RR 0.23 (95% CrI 0.06–0.87)] in reducing laboratory-confirmed influenza. With regard to safety, higher systemic AEs rates after vaccination with 3-IIV, 3-IIV HD, 3-IIV ID, 3-IIV MF59/AS03-adj, quadrivalent inactivated (4-IIV), quadrivalent adjuvanted (4-IIV MF59/AS03-adj), quadrivalent recombinant (4-RIV), 3-LAIV or quadrivalent live attenuated (4-LAIV) vaccines were noted in adults and the elderly [RR 1.5 (95% CrI 1.18–1.89) to 1.15 (95% CrI 1.06–1.23)] compared with placebo. In children, the systemic AEs rate after vaccination was not significantly higher than placebo. Interpretation All vaccines cumulatively achieved major reductions in the incidence of laboratory-confirmed influenza in children, adults, and the elderly. While the live-attenuated was more efficacious than the inactivated vaccine in children, many vaccine types can be used in adults and the elderly. Funding The directorate general of welfare, Lombardy region.","claims":[{"public_id":"cl_ce086d6a8cc9e4cfefdb47203be80f37","status":"active","text":"In adults and elderly, all seasonal influenza vaccines except trivalent inactivated intradermal (3-IIV ID) significantly reduced the risk of laboratory-confirmed influenza compared to placebo, with risk ratios ranging from 0.33 (3-IIV HD) to 0.56 (3-LAIV).","confidence":0.95,"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/claims/cl_ce086d6a8cc9e4cfefdb47203be80f37"},{"public_id":"cl_cc73927bf1f3bb2c8ca2d7b78131d7a8","status":"active","text":"In adults and elderly, several vaccines including 3-IIV, 3-IIV HD, 3-IIV ID, 3-IIV MF59/AS03-adj, 4-IIV, 4-IIV MF59/AS03-adj, 4-RIV, 3-LAIV and 4-LAIV were associated with higher rates of systemic adverse events compared to placebo (RR 1.15 to 1.5), while in children the systemic AE rate after vaccination was not significantly higher than placebo.","confidence":0.9,"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/claims/cl_cc73927bf1f3bb2c8ca2d7b78131d7a8"},{"public_id":"cl_91f62fdabcc2947e4e035146a6aa4517","status":"active","text":"In adults and elderly, trivalent live-attenuated vaccine (3-LAIV) was less efficacious than trivalent inactivated vaccine (3-IIV) in reducing laboratory-confirmed influenza (RR 1.41, 95% CrI 1.04–1.88).","confidence":0.95,"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/claims/cl_91f62fdabcc2947e4e035146a6aa4517"},{"public_id":"cl_a02c6e67686deb032ef706b16b0a6c4f","status":"active","text":"In children, trivalent live-attenuated vaccine (3-LAIV) and trivalent inactivated adjuvanted with MF59/AS03 were more efficacious than trivalent inactivated vaccine (3-IIV) in reducing laboratory-confirmed influenza (RR 0.52 and 0.23 respectively).","confidence":0.95,"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/claims/cl_a02c6e67686deb032ef706b16b0a6c4f"}],"concepts":[{"public_id":"co_01eef2940a267a646a05198d0b5123c2","status":"active","name":"seasonal influenza vaccines","description":"The overall category of vaccines evaluated in the review to prevent seasonal influenza.","types":["vaccine category"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_01eef2940a267a646a05198d0b5123c2"},{"public_id":"co_174b1e3b9ed85b1480baa02a8223f27f","status":"active","name":"trivalent live-attenuated vaccine (3-LAIV)","description":"A live-attenuated trivalent vaccine that was less efficacious than 3-IIV in adults/elderly but more efficacious in children.","types":["vaccine type"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_174b1e3b9ed85b1480baa02a8223f27f"},{"public_id":"co_2ecc19efc382a4902cd60b06a14d8ba4","status":"active","name":"network meta-analysis","description":"The analytical method used to compare multiple vaccines across trials.","types":["method"],"aliases":["NMA"],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_2ecc19efc382a4902cd60b06a14d8ba4"},{"public_id":"co_499f90d86287919c5257252e45d80fa7","status":"active","name":"trivalent inactivated vaccine (3-IIV)","description":"The standard trivalent inactivated vaccine used as comparator in head-to-head analyses.","types":["vaccine type"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_499f90d86287919c5257252e45d80fa7"},{"public_id":"co_4a7de83722ac81733f577724199b6b85","status":"active","name":"systemic adverse events","description":"Safety outcome measuring systemic adverse events after vaccination; higher rates were noted in adults/elderly but not in children.","types":["safety outcome"],"aliases":["systemic AEs"],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_4a7de83722ac81733f577724199b6b85"},{"public_id":"co_6fb5d11908ecb522d8f654589e40dda9","status":"active","name":"trivalent inactivated adjuvanted with MF59/AS03 vaccine","description":"An adjuvanted trivalent inactivated vaccine that was more efficacious than 3-IIV in children (RR 0.23).","types":["vaccine type"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_6fb5d11908ecb522d8f654589e40dda9"},{"public_id":"co_7dd3f5309ce9f7bafbdc315f188cc0c2","status":"active","name":"adults and the elderly","description":"Population aged 18–60 years (adults) and ≥61 years (elderly) included in the review.","types":["population"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_7dd3f5309ce9f7bafbdc315f188cc0c2"},{"public_id":"co_919a7cfdc38301ea7b424d9c27e51929","status":"active","name":"trivalent inactivated high-dose vaccine (3-IIV HD)","description":"A high-dose trivalent inactivated vaccine with the smallest risk ratio (0.33) vs placebo in adults/elderly.","types":["vaccine type"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_919a7cfdc38301ea7b424d9c27e51929"},{"public_id":"co_982f496800f431c716b21024693e695d","status":"active","name":"randomized clinical trials (RCTs)","description":"The study design of the included trials in the review.","types":["study design"],"aliases":["RCTs"],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_982f496800f431c716b21024693e695d"},{"public_id":"co_a2c0954932fbf4fe3a282cabb18cd14b","status":"active","name":"laboratory-confirmed influenza","description":"The primary outcome measure used in the review to assess vaccine efficacy.","types":["outcome","endpoint"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_a2c0954932fbf4fe3a282cabb18cd14b"},{"public_id":"co_d846aa56a493c0b66e60a3171162cab1","status":"active","name":"trivalent inactivated intradermal vaccine (3-IIV ID)","description":"A specific seasonal influenza vaccine administered intradermally; the only vaccine not more effective than placebo in adults/elderly.","types":["vaccine type"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_d846aa56a493c0b66e60a3171162cab1"},{"public_id":"co_e6d04be3c13f6c940520cdeec2cf0348","status":"active","name":"children","description":"Population under 18 years old included in the review.","types":["population"],"aliases":[],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"url":"https://sah.borca.ai/concepts/co_e6d04be3c13f6c940520cdeec2cf0348"}],"external_ids":{"DOI":"10.1016/j.eclinm.2022.101331","ArXiv":null,"PubMed":35360146,"PubMedCentral":"8961170","MAG":null,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"http://www.thelancet.com/article/S258953702200061X/pdf","landing_url":"https://www.semanticscholar.org/paper/ff6768e25bde324a1df0f71a54de2afc537ca743","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":630694,"paper_uid":"230b4f6b-5104-4d3c-b082-aec06483fc1e","canonical_identity":{"paper_id":630694,"paper_uid":"230b4f6b-5104-4d3c-b082-aec06483fc1e","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/241185914"}